Isatuximab

Products

Isatuximab was approved in many countries, in the EU, and in the United States in 2020 as a concentrate for the preparation of an infusion solution (Sarclisa).

Structure and properties

Isatuximab is a chimeric monoclonal antibody derived from IgG1. It is produced by biotechnological methods. The molecular mass is approximately 148 kDa.

Effects

Isatuximab has antitumor and selective cytotoxic properties. The effects are due to binding to the extracellular epitope of the CD38 receptor, resulting in tumor cell death. CD38 is expressed on the cell surface in multiple myeloma. The half-life is 28 days.

Indications

For the treatment of relapsed and refractory multiple myeloma in adults.

Dosage

According to the SmPC. The drug is administered as an intravenous infusion.

Contraindications

  • Hypersensitivity

For complete precautions, see the drug label.

Adverse effects

The most common possible adverse effects include: